Balaji Srinivasan, CEO of bitcoin start-up 21.co, and Jim O'Neill, the managing director of investment firm Mithril Capital Management, were both scheduled to meet with Trump Thursday afternoon. Both "are being considered for positions in the FDA," incoming White House press secretary Sean Spicer said on a daily briefing call.
Srinivasan, also a partner at venture firm Andreessen Horowitz, is an expert in the subjects of digital payments and computational biology, and teaches at Stanford University. Srinivasan's expertise in health regulation stems back to a start-up he co-founded, Counsyl, which offers DNA screening, especially for people considering having children.
Srinivasan has openly criticized the FDA, saying that "big bad pharma does exist, but is only half the story. FDA sets the incentives."
Tweet: Why care about the FDA so much? Well, whether you want a new drug or to get to transhumanism they are the man to beat - or escape, via exit.
O'Neill, who has previously been mentioned as a potential FDA pick, formerly advised top players at Heath and Human Services on drug and research investments. He's also been outspoken about the state of healthcare regulation, speaking on the issue of aging at a conference in 2014.